These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 22251148)

  • 21. [Multi-center trial on the early effects of silodosin on lower urinary tract symptoms associated with benign prostatic hyperplasia].
    Ogawa T; Uemura H; Sano F; Hoshino K; Kita K; Hayashi N; Kagota M; Murakami T; Makiyama K; Miyoshii Y; Nakaigawa N; Yao M; Shimura H; Furuhata A; Fujikawa N; Shioi K; Ueki T; Hara Y; Saitou K; Kawakami S; Satomi Y; Hattori Y; Teranishi J; Kondo K; Kishida T; Saito K; Noguchi K; Fuji H; Yamaguchi T; Kinoshita Y; Nomura S; Yoshida M; Sakai N; Terao H; Matsumoto T; Umemoto S; Ogo Y; Kobayashi K; Noguchi S; Asakura T; Kohdaira T; Iguchi K; Izumi K; Hirano M; Kanno H; Takahashi T; Nukui F; Mokuo Y; Muraoka K; Osada Y; Funahashi M; Kitami K; Sugiura S; Ohta J; Miura T; Ishibashi Y; Masuda M; Komiya A; Suwa Y; Hashiba T; Mitaka K; Kobayashi M; Ohsaka K; Futoshi T; Tsuchiya T; Iwasaki A; Yamashita Y; Matsuzaki J; Kubota Y
    Hinyokika Kiyo; 2008 Dec; 54(12):757-64. PubMed ID: 19174997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia.
    Keating GM
    Drugs; 2015 Feb; 75(2):207-17. PubMed ID: 25575983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates.
    Capitanio U; Salonia A; Briganti A; Montorsi F
    Int J Clin Pract; 2013 Jun; 67(6):544-51. PubMed ID: 23409749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Takao T; Tsujimura A; Kiuchi H; Matsuoka Y; Miyagawa Y; Nonomura N; Iwasa A; Kameoka H; Kuroda H; Matsumiya K; Uchida K; Yoshimura K; Okuyama A
    Int J Urol; 2008 Oct; 15(11):992-6. PubMed ID: 18775032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial.
    Tsumura H; Satoh T; Ishiyama H; Tabata K; Kotani S; Minamida S; Kimura M; Fujita T; Matsumoto K; Kitano M; Hayakawa K; Baba S
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e385-92. PubMed ID: 21664068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of silodosin and tamsulosin on the urethra and cardiovascular system in young and old dogs with benign prostatic hyperplasia.
    Kobayashi S; Tomiyama Y; Tatemichi S; Hoyano Y; Kobayashi M; Yamazaki Y
    Eur J Pharmacol; 2009 Jun; 613(1-3):135-40. PubMed ID: 19389393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia.
    Tatemichi S; Tomiyama Y; Maruyama I; Kobayashi S; Kobayashi K; Maezawa A; Kobayashi M; Yamazaki Y; Shibata N
    Neurourol Urodyn; 2006; 25(7):792-9; discussion 800-1. PubMed ID: 16894620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data.
    Novara G; Chapple CR; Montorsi F
    BJU Int; 2015 May; 115(5):802-14. PubMed ID: 25130493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostatic and extraprostatic alpha-adrenoceptors--contributions to the lower urinary tract symptoms in benign prostatic hyperplasia.
    Andersson KE
    Scand J Urol Nephrol Suppl; 1996; 179():105-11. PubMed ID: 8908675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.
    Matsukawa Y; Gotoh M; Komatsu T; Funahashi Y; Sassa N; Hattori R
    J Urol; 2013 Jan; 189(1 Suppl):S117-21. PubMed ID: 23234615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of alpha-adrenoceptor antagonists therapy on stool form in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Matsumoto S; Kasamo S; Hashizume K
    Low Urin Tract Symptoms; 2020 Jan; 12(1):86-91. PubMed ID: 31464384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Up-regulation of α1a and α1d-adrenoceptors in the prostate by administration of subtype selective α1-adrenoceptor antagonist tamsulosin in patients with benign prostatic hyperplasia.
    Kojima Y; Sasaki S; Kubota Y; Imura M; Oda N; Kiniwa M; Hayashi Y; Kohri K
    J Urol; 2011 Oct; 186(4):1530-6. PubMed ID: 21855934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study].
    Masuda M; Jinza S; Masuko H; Asakura T; Hashiba T
    Hinyokika Kiyo; 2012 Dec; 58(12):671-8. PubMed ID: 23328162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
    Yu HJ; Lin AT; Yang SS; Tsui KH; Wu HC; Cheng CL; Cheng HL; Wu TT; Chiang PH
    BJU Int; 2011 Dec; 108(11):1843-8. PubMed ID: 21592295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficiency and safety of silodosin for treatment of lower urinary tract symptoms, associated of benign prostatic hyperplasia].
    Krivoborodov GG; Tur EI
    Urologiia; 2019 Jun; (2):67-72. PubMed ID: 31162905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat.
    Shimizu S; Shimizu T; Tsounapi P; Higashi Y; Martin DT; Nakamura K; Honda M; Inoue K; Saito M
    PLoS One; 2015; 10(8):e0133798. PubMed ID: 26308715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Six-year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal?
    Yamanishi T; Kaga K; Fuse M; Shibata C; Kamai T; Uchiyama T
    Int J Urol; 2015 Dec; 22(12):1143-8. PubMed ID: 26310102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Silodosin in the treatment of benign prostatic hyperplasia.
    Rossi M; Roumeguère T
    Drug Des Devel Ther; 2010 Oct; 4():291-7. PubMed ID: 21116335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study.
    Shirakawa T; Haraguchi T; Shigemura K; Morishita S; Minayoshi K; Miyazaki J; Yamada Y; Miyake H; Tanaka K; Fujisawa M
    Int J Urol; 2013 Sep; 20(9):903-10. PubMed ID: 23252453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.